Ridaforolimus
- Generic Name
- Ridaforolimus
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C53H84NO14P
- CAS Number
- 572924-54-0
- Unique Ingredient Identifier
- 48Z35KB15K
- Indication
Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.
- Associated Conditions
- -
- Associated Therapies
- -
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Angela Taber MD
- Target Recruit Count
- 12
- Registration Number
- NCT01212627
- Locations
- 🇺🇸
memorial Hospital of Rhode island, Pawtucket, Rhode Island, United States
🇺🇸The Miriam Hospital, Providence, Rhode Island, United States
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01169532
- Locations
- 🇺🇸
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01071304
Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT01043887
Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT01010672
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT00781846
Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 35
- Registration Number
- NCT00770185
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT00739830
Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT00736970
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00704054
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath